AbbVie’s Promising Study on NSCLC Treatment: A Potential Game Changer

Abbvie ((ABBV)) announced an update on their ongoing clinical study.

AbbVie is conducting a Phase 2/3 study titled ‘A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer.’ The study aims to evaluate the safety, efficacy, and optimal dosage of telisotuzumab adizutecan combined with osimertinib, a standard treatment for non-small cell lung cancer (NSCLC), to improve patient outcomes.

The study involves testing an investigational drug, telisotuzumab adizutecan, administered intravenously, in combination with the oral tablet osimertinib. The goal is to determine the best dose for treating NSCLC, a prevalent lung cancer type.

This interventional study is randomized and follows a sequential intervention model. It employs quadruple masking to ensure unbiased results, focusing primarily on treatment efficacy.

The study began on May 27, 2025, with its primary completion and estimated overall completion dates yet to be announced. The latest update was submitted on August 27, 2025, indicating ongoing recruitment.

AbbVie’s study could significantly impact its stock performance by potentially introducing a new treatment option for NSCLC, enhancing its market position. This development may influence investor sentiment positively, considering the competitive landscape in cancer treatment innovations.

The study is actively recruiting, with further details available on the ClinicalTrials portal.